Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tuomo Lapveteläinen"'
Autor:
Julio Delgado, Caroline Voltz, Milena Stain, Tuomo Lapveteläinen, Susanne Urach, Johanna Lähteenvuo, Karri Penttilä, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e604 (2021)
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs
Externí odkaz:
https://doaj.org/article/c1b190f2755848fa85807fd6f89529fa
Autor:
Beatriz Florez, Greg Markey, Mariapaola Caleno, Odoardo Maria Olimpieri, Daniela Melchiorri, Doris Johanna Hovgaard, Sinan Bardakci Sarac, Karri Penttilä, Tuomo Lapveteläinen, Jonas Bergh
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have recei
Externí odkaz:
https://doaj.org/article/299d78087e884913bdad06e045b92d29
Autor:
Francesco Pignatti, Kyriaki Tzogani, Lucía Lopez Anglada, Johanna Lähteenvuo, Carolina Prieto, Harald Enzmann, Karri Penttilä, Blanca Garcia-Ochoa, Tuomo Lapveteläinen, Christian Gisselbrecht, Julio Delgado
Publikováno v:
Oncologist
On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb53c9d316e99987a0eaa785466117c
https://doi.org/10.1002/onco.13592
https://doi.org/10.1002/onco.13592
Autor:
Karri Penttila, Susanne Urach, Milena Stain, Caroline Voltz, Christian Gisselbrecht, Tuomo Lapveteläinen, Johanna Lähteenvuo, Julio Delgado, Harald Enzmann, Francesco Pignatti
Publikováno v:
HemaSphere
HemaSphere, Vol 5, Iss 7, p e604 (2021)
HemaSphere, Vol 5, Iss 7, p e604 (2021)
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f3476dce9d031c3e9bc54627edad33
https://pubmed.ncbi.nlm.nih.gov/34235401
https://pubmed.ncbi.nlm.nih.gov/34235401
Autor:
João Freire, Paola Coppola, Karri Penttilä, Beatriz Flores, Silva Márcia, Silvia Domingo Roige, Kyriaki Tzogani, Francesco Pignatti, Robert Hemmings, Janet Koenig, Yolanda Barbachano, Susan Cole, Tuomo Lapveteläinen
Publikováno v:
Oncologist
On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095fa63b8fe5874f491b0086b80a6caf
https://pubmed.ncbi.nlm.nih.gov/32282100
https://pubmed.ncbi.nlm.nih.gov/32282100
Autor:
Sinan B. Sarac, Jonas Bergh, Tomas Salmonson, Christian Gisselbrecht, Greg Markey, Karri Penttilä, Kyriaki Tzogani, Mariapaola Caleno, Francesco Pignatti, Doris Hovgaard, Daniela Melchiorri, Tuomo Lapveteläinen, Odoardo Maria Olimpieri, Beatriz Florez
Publikováno v:
ESMO Open
ESMO Open, Vol 4, Iss 5 (2019)
ESMO Open, Vol 4, Iss 5 (2019)
On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da6b07d3543ab4d6c16ec46f79ad711d
https://pubmed.ncbi.nlm.nih.gov/31555488
https://pubmed.ncbi.nlm.nih.gov/31555488